We’ll start off by discussing results from the I-SPY 2 trial on the efficacy of pembrolizumab plus chemotherapy in HER2-negative breast cancer. Then, we’ll move on to a report covering racial disparities in diagnostic and treatment technology as related to outcomes in patients with colorectal cancer. Lastly, we’ll review a long list of treatments for which the FDA recently granted Priority Review.

Coverage of stories discussed this week on ascopost.com:

Addition of Pembrolizumab to Neoadjuvant Chemotherapy in Early-Stage HER2-Negative Breast Cancer

Diagnostic and Treatment Technology Disparities Among Patients With Colorectal Cancer